KOD Key Statistics, Chart & Performance
The current stock price of KOD is 25.05 USD. In the past month the price increased by 35.48%. In the past year, price increased by 195.75%.
KOD Latest News, Press Relases and Analysis
KOD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.6 | 394.11B | ||
| AMGN | AMGEN INC | 14.35 | 169.00B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 148.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.17 | 110.88B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.39 | 72.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 814.14 | 54.85B | ||
| INSM | INSMED INC | N/A | 41.41B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.5 | 25.80B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.05 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B | ||
| INCY | INCYTE CORP | 14.82 | 18.68B |
Related stock screener links
About KOD
Company Profile
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 121 full-time employees. The company went IPO on 2018-10-04. The firm has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. The company is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Company Info
KODIAK SCIENCES INC
1250 Page Mill Road
Palo Alto CALIFORNIA 94304 US
CEO: Victor Perlroth
Employees: 121
Phone: 16502810850
KODIAK SCIENCES INC / KOD FAQ
Can you describe the business of KODIAK SCIENCES INC?
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 121 full-time employees. The company went IPO on 2018-10-04. The firm has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. The company is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
What is the current price of KOD stock?
The current stock price of KOD is 25.05 USD. The price decreased by -4.17% in the last trading session.
Does KOD stock pay dividends?
KOD does not pay a dividend.
What is the ChartMill technical and fundamental rating of KOD stock?
KOD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists KOD stock?
KOD stock is listed on the Nasdaq exchange.
Can you provide the market cap for KODIAK SCIENCES INC?
KODIAK SCIENCES INC (KOD) has a market capitalization of 1.33B USD. This makes KOD a Small Cap stock.
KOD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KOD. When comparing the yearly performance of all stocks, KOD is one of the better performing stocks in the market, outperforming 98.88% of all stocks.
KOD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KOD. While KOD seems to be doing ok healthwise, there are quite some concerns on its profitability.
KOD Financial Highlights
Over the last trailing twelve months KOD reported a non-GAAP Earnings per Share(EPS) of -4.12. The EPS decreased by -12.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.66% | ||
| ROE | -917.34% | ||
| Debt/Equity | 0 |
KOD Forecast & Estimates
12 analysts have analysed KOD and the average price target is 21.71 USD. This implies a price decrease of -13.33% is expected in the next year compared to the current price of 25.05.